Drugs / D-mannose
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03395288 | Mar 2018 → Apr 2020 | urinary tract infection | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03497598 | May 2018 → May 2020 | urinary tract infection | Kantonsspital Aarau | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06360055 | Apr → Nov 2024 | — | Peking University Third Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d-Mannose | “d-Mannose is a well-tolerated nutraceutical, but further research is needed to determine whether d-mannose in combination with VET has a significant, beneficial effect beyond...” PMID 36808931 ↗ Oct 20223“Subjects will take 3g (1g*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose...” NCT06360055 ↗ “D-mannose is a sugar part of normal human metabolism found within most diets.” PMID 36041061 ↗ Aug 2022 |
| Route | Oral | “ready to be dissolved in 100ml of water for oral Ingestion” NCT03497598 ↗ |